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In Brief
During apoptosis, mitochondrial outer
membrane permeabilization (MOMP) is
widespread, leading to rapid cell death.
Here, Ichim et al. demonstrate thatMOMP
can also be engaged in a minority of
mitochondria without killing the cell.
Instead, minority MOMP triggers
caspase-dependent DNA damage and
genomic instability, thereby promoting
transformation and tumorigenesis.
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During apoptosis, themitochondrial outermembrane
is permeabilized, leading to the release of cyto-
chrome c that activates downstream caspases.Mito-
chondrial outer membrane permeabilization (MOMP)
has historically been thought to occur synchronously
and completely throughout a cell, leading to rapid
caspase activation and apoptosis. Using a new imag-
ing approach, we demonstrate that MOMP is not an
all-or-nothing event. Rather, we find that a minority
ofmitochondria can undergoMOMP in a stress-regu-
lated manner, a phenomenon we term ‘‘minority
MOMP.’’ Crucially, minority MOMP leads to limited
caspase activation, which is insufficient to trigger
cell death. Instead, this caspase activity leads to
DNA damage that, in turn, promotes genomic insta-
bility, cellular transformation, and tumorigenesis.
Our data demonstrate that, in contrast to its well-es-
tablished tumor suppressor function, apoptosis also
has oncogenic potential that is regulated by the
extent of MOMP. These findings have important im-
plications for oncogenesis following either physio-
logical or therapeutic engagement of apoptosis.
INTRODUCTION
Following most apoptotic stimuli, the pro-apoptotic BCL-2 fam-
ily members Bax and Bak permeabilize the outer membrane of
the mitochondria, an event termed ‘‘mitochondrial outer mem-
brane permeabilization’’ (MOMP). MOMP leads to rapid cell860 Molecular Cell 57, 860–872, March 5, 2015 ª2015 The Authorsdeath by releasing mitochondrial proteins including cytochrome
c that activate caspases (Tait and Green, 2010). However, even
in the absence of caspase activity, cells typically die onceMOMP
has occurred, most likely due to progressive mitochondrial dys-
function (Lartigue et al., 2009; Tait et al., 2014). Due to these
catastrophic effects, MOMP is often considered the point of no
return in the apoptotic program. Mitochondrial apoptosis plays
numerous important pathophysiological roles. In cancer, inhi-
bition of apoptosis both promotes tumorigenesis and impedes
anti-cancer therapeutic efficacy (Delbridge et al., 2012). Apo-
ptotic inhibition is often achieved by upregulation of anti-apo-
ptotic BCL-2 family members that prevent MOMP. This has
led to the development of new anticancer drugs, called BH3-
mimetics, which neutralize anti-apoptotic BCL-2 function (Ni
Chonghaile and Letai, 2008).
Live-cell imaging has demonstrated that mitochondrial perme-
abilization is often an all-or-nothing event (Goldstein et al., 2000).
Widespread mitochondrial permeabilization underpins the lethal
effects of MOMP by ensuring robust caspase activity, or in its
absence, massive mitochondrial dysfunction. In some limited cir-
cumstances, cells can survive MOMP. For example, growth fac-
tor-deprived neurons can survive MOMP due to a failure to prop-
erly engage caspase activity (Deshmukh and Johnson, 1998;
Martinou et al., 1999; Wright et al., 2004). In proliferating cells,
expression of the key glycolytic enzyme GAPDH can promote
cell survival followingMOMPprovidedcaspaseactivity is inhibited
(Colell et al., 2007). We have previously found that the ability of
cells to surviveMOMPdepends on a fewmitochondria that evade
permeabilization and re-populate the cell (Tait et al., 2010).
Whereas earlier studies demonstrated that strong pro-
apoptotic stimuli lead to rapid, synchronous, and complete
MOMP, technical limitations have made it impossible to study
the effects of sub-lethal stresses on individual mitochondria.
Here, we use newly developed imaging techniques to
demonstrate that MOMP can occur in a limited subset of mito-
chondria following a sub-lethal stress. Crucially, this limited
MOMP leads to caspase activation, which, while insufficient to
trigger cell death, leads to limited cleavage of key caspase sub-
strates. This in turn drives DNA-damage and genomic instability,
promoting transformation and tumorigenesis. Importantly, our
data argue that the mitochondrial apoptotic pathway may exert
either a tumor suppressor or oncogenic function depending
upon the extent of MOMP.
RESULTS
Limited Mitochondrial Permeabilization Occurs
in the Absence of Cell Death
Mitochondrial permeabilization during apoptosis is wides-
pread such that most or all mitochondria within a cell undergo
MOMP; this effectively commits a cell to die. However, the poten-
tial for sub-lethal apoptotic stresses to engageMOMP in a limited
number of mitochondria has not been tested. To investigate this,
we used ABT-737, the prototypic BH3-mimetic compound that
sensitizes to apoptosis by antagonizing anti-apoptotic BCL-2
family proteins (Oltersdorf et al., 2005). HeLa or U2OS cells
were treatedwith varying concentrations of ABT-737, enantiomer
(less-active stereoisomer of ABT-737) or the apoptosis-inducer
staurosporine (STS) and analyzed for apoptosis by Annexin V
staining and flow cytometry. Importantly, whereas STS triggered
apoptosis, treatment with ABT-737 at varying doses failed to
induce detectable apoptosis (Figure 1A). Similarly, live-cell imag-
ing using the cell impermeable dye Sytox green also failed to
reveal a cytotoxic effect of ABT-737 treatment (Figure S1A).
Finally, BH3-mimetic treatment at the indicated doses had no
effect on long-term cell survival as determined by clonogenic
assay (Figure S1B). We next asked if mitochondrial permeabiliza-
tion occurred following this non-lethal BH3-mimetic treatment.
HeLa cells were treated with ABT-737 or, as a positive control,
Actinomycin D (Act D) and cytosolic fractions were probed for
the presence of cytochrome c to detect MOMP. As expected,
Act D treatment led to MOMP as demonstrated by the detection
of cytochrome c in the cytosolic extract (Figure 1B). Surprisingly,
treatment with a non-lethal dose of ABT-737 also led to low, but
detectable levels of MOMP, implying that MOMP could be
engaged without killing the cell (Figure 1B).
In caspase-proficient cells, complete MOMP invariably repre-
sents a point of no return; we therefore reasoned that MOMP
could only be non-lethal if it occurred in aminority ofmitochondria
(called hereafter minority MOMP). To test this possibility, we
developed a newapproach to specifically visualize permeabilized
mitochondria using fluorescent protein re-localization and chem-
ically dimerizable FKBP/FRB domains (Belshaw et al., 1996).
Two fluorescent probes were constructed: a cytosolic probe
comprising ofGFP fused to a FKBPdomain (cytoGFP) andamito-
chondrial targeted probe (mitoCherry) comprising of mCherry
fused to an FRB domain and the mitochondrial anchoring
sequence of Apoptosis Inducing Factor (AIF) (Otera et al., 2005).
In thepresenceof chemical heterodimerizer (A/Cheterodimerizer,
AP21967), the two probes can only co-localize on mitochondria
followingMOMPwhencytoGFPcangain access to themitochon-
drial inner membrane (Figure 1C). To validate this method, weMtreatedU2OScellswith the apoptotic stimulusActD. Importantly,
Act D treatment led to robust mitochondrial re-localization of cy-
toGFP only in the presence of dimerizer that, as expected, was
prevented by blocking MOMP by expression of BCL-xL (Figures
1D, S1C, and S1D). In line with this method marking MOMP
as the key initiating apoptotic event, cytoGFP re-localization
preceded caspase dependent apoptotic effects including cell
shrinkage, rounding, and plasma membrane blebbing (Movie
S1). Further verifying this technique, Act D-inducedmitochondrial
localizationofGFPwasonly observed in cells inwhichMOMPhad
occurred, as demonstrated by the cytosolic release of Smac
mCherry (a verified reporter of MOMP) (Figure S1E and Movie
S2) (Tait et al., 2010). These fluorescent tools thus allow us to
detect the permeabilization of individual mitochondria, and
thereby assay for the presence of minority MOMP.
Using this approach, we investigated the extent of MOMP
following sub-lethal apoptotic stimuli. Strikingly, following ABT-
737 treatment, we were able detect MOMP in a limited number
of mitochondria in both HeLa and U2OS cells (Figure 1E). Con-
firming their permeabilization, mitochondria with relocalized
CytoGFP had also released Smac-mCherry and cytochrome c
(Figures S1F andS1G). The percentage of cells displayingminor-
ity MOMP increased in a dose-dependent and BCL-xL inhibit-
able manner following ABT-737 treatment (Figure 1F). Impor-
tantly, using live-cell imaging, cells displaying minority MOMP
failed to undergo cell death during extended periods of analysis
(Figure S1H). Collectively, these data demonstrate that MOMP
can occur in a limited number of mitochondria in response to
ABT-737 treatment without leading to cell death.
Minority MOMP Engages Sub-Lethal Caspase Activity
We next sought to understand the consequences of minority
MOMP, and in particular, whether it might lead to activation of
caspases at sub-apoptotic levels. We first quantified the extent
of minority MOMP in HeLa cells. This revealed an average of
2.5% of a cell’s mitochondria undergoing permeabilization fol-
lowing sub-lethal ABT-737 treatment (Figure 2A). Together with
previously published criteria, this allowed us to adapt a mathe-
matical HeLa cell model of the apoptosis execution phase
(Rehm et al., 2006) to perform in silico simulations of the conse-
quences of minority MOMP on the efficiency of caspase-3 pro-
cessing and activation. Importantly, despite the presence of
amplifying feedback loops which ensure rapid and full caspase
activation in response to regular MOMP, simulations for minority
MOMP conditions demonstrate that caspase-3 would be pro-
cessed and activated sub-maximally and therefore, potentially,
at sub-lethal levels (Figures 2B andS2A). To experimentally verify
this, U2OS and HeLa cells were treated with the BH3-mimetic
ABT-737 in the presence or absence of caspase inhibitor qui-
nolyl-valyl-O-methylaspartyl-[2,6-difluoro- phenoxy]-methyl ke-
tone (Q-VD-OPh). Treatment with a wide range of sub-lethal
doses of ABT-737 triggered caspase activity as evidenced by
pro-caspase-3 processing and PARP cleavage, effects that
were blocked by caspase inhibition (Figures S2B and S2C). We
next compared caspase activity between conditions that engage
minorityMOMPandapoptotic conditions.Cellswere treatedwith
ABT-737 to induce minority MOMP or with TNF/CHX or Act D to
engage apoptosis (Figures 2C–2E and S2D). We determinedolecular Cell 57, 860–872, March 5, 2015 ª2015 The Authors 861
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Figure 1. Limited Mitochondrial Outer Membrane Permeabilization Occurs without Triggering Cell Death
(A) HeLa and U2OS cells were treated for 3 hr with different concentrations of ABT-737 or enantiomer (ENA, 10 mM) or with staurosporine (STS, 1 mM) for 12 hr and
analyzed by flow cytometry for Annexin V-positive cells. Data represent mean ± SEM of three independent experiments.
(B) HeLa cells were treated for 3 hr with different concentrations of ABT-737 or actinomycin D for 6 hr (Act D, 1 mM), and cytosolic extracts were western blotted for
cytochrome c, COX IV, and b-tubulin. WCE, whole-cell extract.
(C) Schematic representation of GFP relocalization-based MOMP detection method. DM, chemical heterodimerizer; IMM, inner mitochondrial membrane; IMS,
intermembrane space; OMM, outer mitochondrial membrane.
(D) U2OS cells expressing vector or BCL-xL together with CytoGFP/MitoCherry were treated with Act D (1 mM) for 3 hr in the presence of heterodimerizer and
imaged by confocal microscopy.
(E) HeLa or U2OS cells expressing CytoGFP/MitoCherry were treated with vehicle or ABT-737 (5 mM) or enantiomer (5 mM, ENA) for 3 hr and imaged by confocal
microscopy. Arrows denote permeabilized mitochondria. Line scans represent variation in red and green fluorescence intensity along the denoted line.
(F) U2OS cells expressing CytoGFP/MitoCherry were treated for 3 hr with ABT-737, and minority MOMP was quantified. Data represent mean ± SEM of three
independent experiments.
*p < 0.05, compared versus control. See also Figure S1 and Movies S1 and S2.executioner caspase-3 and -7 activity, by detection of their
active, cleaved fragment (Figure 2C) or by their activity-depen-
dent precipitation using biotin-Val-Ala-Asp-Fluoromethyl Ketone
(b-VAD) (Figure 2D). Both approaches demonstrated that cas-
pase-3 and -7 activity was detectable but significantly less in862 Molecular Cell 57, 860–872, March 5, 2015 ª2015 The AuthorsABT-737 treated cells undergoing minority MOMP compared
with apoptotic cells (Figures 2C and 2D). Levels of active cas-
pase-9, precipitatedwith b-VAD, were also detectable but signif-
icantly less in ABT-737 treated cells undergoing minority MOMP
in comparison to apoptotic cells (Figure 2E). In line with ABT-737
activating the mitochondrial caspase pathway, ABT-737 treat-
ment led to caspase-9 but not caspase-8 activation (Figure 2E).
Collectively, these data argue that minority MOMP can engage
sub-lethal caspase activity. To corroborate these findings, we
used a recently developed caspase reporter protein (VC3AI)
that fluoresces following caspase-mediated cleavage (Zhang
et al., 2013). As validation, apoptotic treatments led to an
increase in fluorescence in VC3AI expressing HeLa cells in a
caspase-dependent manner, whereas cells expressing the
non-cleavable control (ncVC3AI) remained non-fluorescent (Fig-
ure S2E). Significantly, flow cytometry analysis demonstrated
that ABT-737 treatment led to a detectable increase in caspase
activity in viable cells that was inhibited by the caspase inhibitor
Q-VD-OPh, further supporting the hypothesis that minority
MOMP triggers sub-lethal caspase activation (Figure 2F). We
then treated HeLa cells co-expressing Smac-mCherry together
with either VC3AI or ncVC3AI with the BH3-mimetic ABT-737.
In line with the flow cytometry data, treatment with ABT-737
specifically increased the percentage of cells displaying weak
caspase-dependent fluorescence (Figures 2G, 2H, and S2F).
Importantly, cells exhibiting caspase-activity failed to display
apoptotic, widespread MOMP because Smac-mCherry re-
mained localized in the mitochondria (Figure 2G). We next deter-
mined if cells displaying sub-lethal caspase activity could survive
long-term.HeLacells expressing theVC3AI reporterwere treated
either with ABT-737 to engage minority MOMP dependent cas-
pase activity or Act D to trigger mitochondria-dependent
apoptosis. Equal numbers of caspase active (GFP-positive cells)
from both conditions were sorted and compared for clonogenic
survival versus caspase inactive, GFP-negative cells (Figures 2I
and S2G). Importantly, similar clonogenic survival was observed
comparing ABT-737 treated caspase active versus inactive cells;
in contrast, stimulation of mitochondrial dependent apoptosis
by Act D prevented clonogenic outgrowth (Figure 2I). Taken
together, these data demonstrate that minority MOMP can
engage low level caspase activity under which cells can survive.
Minority MOMP Induces Caspase-Dependent
DNA Damage
DNA fragmentation is a classical apoptotic hallmark mediated by
caspase-activated DNase (CAD) (Sakahira et al., 1998). We hy-
pothesized that limited caspase activity following minority
MOMPmight lead to low-level CAD activation, and, in turn, to in-
duction of DNA damage in surviving cells. To test this, we treated
HeLa and U2OS cells with ABT-737 in the presence or absence
of Q-VD-OPh and analyzed for gH2A.X as readout for DNA dam-
age. Importantly, in both cell lines, non-lethal treatment with BH3
mimetic led to caspase-dependent DNA damage as demon-
strated by a caspase-dependent increase in gH2A.X (Figure 3A).
Importantly, the extent of DNA-damage (measured by gH2A.X
foci) correlated with minority MOMP, implicating a causal rela-
tionship between the two (Figures 3B and 3C). The ability of
BH3 mimetics to engage DNA-damage in a caspase-dependent
manner was also observed in other cell lines (Figure S3A). Further
demonstrating caspase-dependent DNA damage, ABT-737
treatment also led to an increase in DNA breaks, measured by
comet assay and Ser15 p53 phosphorylation dependent on cas-
pase function, mirroring gH2A.X levels (Figures 3D, 3E, and S3B).MAlthough p53 independent, induction of DNA damage depended
on mitochondrial caspase activation, because overexpression
of BCL-xL (HeLa), deletion of Bax (HCT-116) or Bax and Bak in
murine embryonic fibroblasts (MEF), or knockdown of APAF-1
(HeLa) prevented BH3 mimetic-induced gH2A.X (Figures 3F–
3H and S3C–S3E). Supporting these findings, direct, non-lethal
activation of caspase-9 by chemical dimerization also led to
DNA damage (Figures 3I and S3F).
Because these data clearly demonstrate caspase-dependent
activation of a DNA damage response, we next tested whether
this effect is mediated by CAD activation. Caspase-3 activity is
required for CAD activation through cleavage of its inhibitor
ICAD. Consistent with caspase-3 and CAD-dependent DNA
damage downstream of minority MOMP, gH2A.X was not
observed following ABT-737 treatment of caspase-3 deficient
MCF-7 cells in contrast to caspase-3 reconstituted MCF-7 (Fig-
ure S3G). To directly test the involvement of CAD in minority
MOMP-induced DNA damage, we used CRISPR/Cas9 genome
editing to generate CAD-deficient HeLa and U2OS cells (Fig-
ure 3J). In both cell lines, CAD deletion prevented BH3 mimetic
induction of gH2A.X, demonstrating its requirement for minority
MOMP-induced DNA damage (Figure 3J). Similar results were
observed following CAD knockdown by siRNA (Figure S3H). In
line with these findings, CAD deletion also effectively prevented
ABT-737 induced DNA breaks, as determined by comet assay
(Figure 3K). Furthermore, we also found that ICAD is cleaved
following induction of minority MOMP, thereby supporting CAD
activation (Figure S3I). Finally, we addressed if minority MOMP
also promotes DNA damage in vivo. Mice were administered
one dose of ABT-737 (either 75 mg/kg or 125 mg/kg) or ad-
ministered daily with ABT-737 (75 mg/kg) over a 3-day period.
Strikingly, a single dose of ABT-737 resulted in a significant
increase of gH2A.X immunoreactivity in the small intestine of
mice (Figure 3L). Repeated dosing did not result in an increase
in gH2A.X immunoreactivity, potentially due to resolution of
DNA damage in between doses (Figure S3J). Although not an
absolute measure of apoptosis, because it detects cells only
transiently during apoptosis, TUNEL staining failed to reveal
any evidence of apoptosis following all ABT-737 treatments (Fig-
ures 3L and S3J). Collectively, these data show that sub-lethal
stresses, causing minority MOMP, can trigger caspase-depen-
dent DNA damage both in vitro and in vivo.
Sub-Lethal BH3-Only and Apoptotic Stress Induce
Minority MOMP and DNA Damage
Although our data demonstrate that the BH3 mimetic drug ABT-
737 triggers minority MOMP and DNA damage, we sought to
demonstrate that these effects also occur following MOMP trig-
gered through other means. BH3-only proteins are the endoge-
nous inducers of MOMP through their ability to activate Bax
and Bak. Therefore, we next asked whether BH3-only proteins
themselves could also engage minority MOMP. For this purpose,
we generated a MelJuSo cell line expressing the BH3-only pro-
tein tBID under a doxycycline inducible promoter.Whereas doxy-
cycline addition at 1 mg/ml led to robust tBID expression and
apoptotic cell death, we were able to titrate doxycycline down
to induce non-lethal tBID expression (Figures 4A, 4B, and S4A–
S4D). We assessed whether expression of tBID at non-lethalolecular Cell 57, 860–872, March 5, 2015 ª2015 The Authors 863
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Figure 2. Minority MOMP Engages Sub-Lethal Caspase Activity
(A) U2OS and HeLa cells expressing CytoGFP/MitoCherry were treated or not with ABT-737 (10 mM for 3 hr in the presence of dimerizer) to induce minority
MOMP, and then z stack confocal imaging was performed. Act D (1 mM) was used to induce complete MOMP. Mitochondrial volume was measured using
ImageJ. Data represent mean of permeabilized mitochondrial volume ± SEM from ten cells per condition.
(B) Data from (A) were used as inputs into a mathematical HeLa cell model of apoptosis execution signaling to calculate the consequences of minority MOMP on
the efficacy of procaspase-3 processing.
(C) HeLa and U2OS cells were treated with ABT-737 (10 mM) or TNF/CHX (20 ng/ml TNF and 1 mg/ml CHX) for 3 hr, and cell extracts were western blotted for
caspases-3 and -7.
(D) Biotinylated-VAD-FMK (bVAD) was incubated with HeLa cells for 1 hr following 3 hr treatments with the indicated stimuli. Cell lysates and precipitated proteins
were western blotted for caspases-3 and -7.
(legend continued on next page)
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levels could also trigger minority MOMP. Importantly, sub-lethal
amounts of tBID (induced by 2.5 and 1 ng/ml doxycycline) led
to minority MOMP as detected by the presence of cytochrome
c in the cytosol (Figure 4C). We aimed to validate these findings
using our method to detect MOMP via GFP re-localization.
Non-lethal levels of tBID expression led to a clear increase in cells
displaying minority MOMP in a manner that could be prevented
through co-expression of BCL-xL (Figures 4D and 4E). Impor-
tantly, as was observed for BH3-mimetic treatment, the caspase
inhibitor Q-VD-OPh also prevented H2A.X phosphorylation upon
induction of sub-lethal levels of tBID (Figure 4F). We next ad-
dressed if a physiological apoptotic stimulus could also trigger
minority MOMP and DNA-damage. Accordingly, sub-lethal treat-
ment of U2OScellswith FAS ligand triggeredminorityMOMPand
DNA-damage in a BCL-xL and caspase-inhibitable manner (Fig-
ures 4G, 4H, andS4E). Similarly, sub-lethal treatment of cells with
the proteasome inhibitor MG132 also induced minority MOMP
(Figure 4I). Collectively, these data demonstrate that similar to
BH3-mimetics, apoptotic stimuli and pro-apoptotic BH3-only
proteins also induce minority MOMP and DNA damage.
JNK Regulates the DNA Damage Response
DNA damage-induced phosphorylation of H2A.X at S139 often
occurs via the PI3K-related kinase family members ATM, ATR,
andDNA-PK (Jackson andBartek, 2009; Shiloh, 2003). However,
we did not observe any significant increase in activated, phos-
phorylated ATM or ATR kinase following sub-lethal ABT-737
treatment (Figure 5A). Moreover, RNAi-mediated knockdown of
ATM, ATR, or DNA-PK failed to affect BH3 mimetic-induced
gH2A.X levels (Figures S5A and S5B). Besides ATM, ATR, and
DNA-PK, c-Jun N-terminal kinase (JNK) has also been found to
mediate H2A.X phosphorylation in some settings (Lu et al.,
2006). Importantly, sub-lethal treatment with ABT-737 led to a
caspase-dependent increase in JNK1/2 activation mirroring
levels of gH2A.X (Figure 5B). JNK activation following ABT-737
administration was also detected in vivo in the small intestine
(Figure 5C). To directly investigate the role of JNK in H2A.X phos-
phorylation, we used RNAi. Combined knockdown of JNK1/2 or
selective knockdown of JNK2 effectively prevented ABT-737
induced gH2A.X implicating a direct role for JNK2 in H2A.X phos-
phorylation (Figures 5D and 5E). Accordingly, RNAi-mediated
knockdown of CAD largely inhibited JNK1/2 phosphorylation
(Figure 5F). These results identify JNK2 as a key player in the mi-
nority MOMP-induced DNA damage response.(E) As in (D), except HeLa cells were pre-incubated for 1 hr with bVAD and treate
(20 ng/ml TNF and 1 mg/ml CHX). Proteins were precipitated with neutravidin a
caspases-8 and -9.
(F) HeLa cells stably expressing the caspase activity reporter (VC3AI) or non-cleav
absence of Q-VD-OPh (10 mM). GFP mean fluorescence intensity of the viable
fluorescence over control. Data represent mean ± SEM of four independent exp
(G) HeLa cells stably expressing VC3AI together with Smac-mCherry were treated
cells.
(H) Quantification of percentage of GFP-positive cells following ABT-737 (10 mM
mean ± SEM of three independent experiments.
(I) HeLa VC3AI cells were treated with ABT-737 (10 mM) for 24 hr or Act D (0.5 mM)
and GFP-negative cells (ABT-737 treated cells) were sorted by flow cytometry a
dependent experiments.
*p < 0.05, compared versus control. See also Figure S2.
MMinority MOMP Promotes Genomic Instability
Based on our results, we hypothesized that by causing DNA
damage, minority MOMP may promote genomic instability and
transformation. To test this possibility, we repeatedly treated
HeLa and U2OS cells with sub-lethal doses of ABT-737 for five
(P5) or ten passages (P10). Following blockage of cytokinesis,
we then quantified the number of cells with micronuclei, a well-
established marker for chromosomal damage (Figure S6A)
(Fenech, 2007). Strikingly, U2OS and HeLa cells displayed a
significant increase in micronuclei number following ABT-737
treatment in a dose-dependent manner (Figures 6A and S6B).
Ectopic BCL-xL expression inhibited micronuclei accumulation
in U2OS cells, confirming that the observed genomic instability
required mitochondrial permeabilization (Figure 6B). In an
analogous manner, induction of sub-lethal levels of the BH3-
only protein tBID in MelJuSo cells also promoted micronuclei
accumulation in a dose-dependent manner (Figure 6C). Micro-
nuclei accumulation following tBID expression was reduced to
control levels by the caspase inhibitor Q-VD-OPh, demon-
strating a requirement for caspases in minority MOMP-induced
chromosomal damage (Figure 6C).
DNA damage can also lead to gene amplification, a delete-
rious event that contributes to oncogene activation. We used
the PALA assay to test if minority MOMP can trigger gene ampli-
fication (Mathew et al., 2009). PALA (N-phosphonoacetyl-L-
aspartate) prevents pyrimidine synthesis by inhibiting the CAD
enzyme (carbamyl phosphate synthetase/aspartate transcar-
bamylase/dihydro-orotase; note that this enzyme shares an
abbreviation with, but is distinct from, caspase-activated DNase
discussed previously). Resistance to PALA treatment in murine
cells is mediated solely through Cad gene amplification. Various
murine cell lines (PDAC, 3T3-SA, and WEHI-S) were repeatedly
treated with BH3 mimetic, then assayed for amplification of the
Cad locus and resistance to PALA treatment. Crucially, ABT-
737 treatment promoted clonogenic survival in all tested murine
cell lines following PALA treatment (Figures 6D and S6C), consis-
tent with genome instability-driven Cad locus amplification.
In line with this result, qPCR revealed that ABT-737 treatment
induced Cad gene amplification in all three cell lines (Figure 6E).
Importantly, BCL-xL overexpression in PDAC cells inhibited
ABT-737-induced PALA resistance and Cad gene amplification,
implicating a key role of minority MOMP in gene amplification
(Figures 6F–6H, S6D, and S6E). Collectively, these results
demonstrate that minority MOMP causes genomic instability.d for 3 hr with ABT-737 (10 mM) or 16 hr Act D (16 hr, 1 mM) or 3 hr TNF/CHX
garose resin. Cell lysates and precipitated proteins were western blotted for
able control (ncVC3AI) were treated for 24 hr with 10 mMABT-737 in presence or
cells was quantified by flow cytometry. Results represent the fold increase in
eriments.
as in (F) and imaged for GFP. Arrows denote caspase reporter (GFP)-positive
) treatment in the presence or absence of Q-VD-OPh (10 mM). Data represent
, and equal numbers of GFP-positive cells (ABT-737 and Act D treated sample)
nd assessed for clonogenic survival. Data represent mean ± SEM of three in-
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Figure 3. Minority MOMP Induces Caspase-Dependent DNA Damage
(A) HeLa and U2OS cells were treated for 3 hr with indicated sub-lethal doses of ABT-737 or enantiomer (10 mM, ENA) in presence or absence of caspase inhibitor
Q-VD-OPh (10 mM). Cell lysates were for probed by western blot for gH2A.X and actin (as loading control).
(legend continued on next page)
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Minority MOMP Promotes Transformation
and Tumorigenesis
Genomic instability can promote oncogenic transformation.
Therefore, we investigated if minorityMOMP-induced DNAdam-
age leading to genomic instability could potentiate E1A/KRAS-
induced transformation in primary mouse embryonic fibroblasts
(MEF). Primary MEFs were treated with sub-lethal doses of ABT-
737 prior to transformation with E1A/KRAS. Remarkably, BH3-
only stress was able to potentiate the transforming ability of
E1A/KRAS in primary cells in a dose-dependent manner (Figures
7A and 7B). We next tested if minority MOMP could promote
transformation in a different setting. Primary MEF deficient
in the tumor suppressor p19Arf were treated with enantiomer
or ABT-737 in the presence or absence of caspase-inhibitor
Q-VD-OPh (Figure S7A). Additionally, primary p19Arf deficient
MEF expressing BCL-xL or empty vector were treated with
ABT-737 (Figures S7B and S7C). Following treatment, cellular
transformation was assessed by anchorage-independent
growth in soft agar. Strikingly, ABT-737 treatment led to transfor-
mation that was completely prevented by inhibiting caspases
(with Q-VD-OPh) or by inhibiting MOMP through BCL-xL expres-
sion (Figures 7C and 7D). We next compared ABT-737 or enan-
tiomer treated p19Arf null MEF for their tumorigenic potential
in vivo following subcutaneous injection in CD1-Nude mice.
Significantly, ABT-737 treated MEF formed tumors much more
rapidly than enantiomer-treated MEF (Figure 7E). Collectively,
these results demonstrate that minority MOMP promotes both
cellular transformation and tumorigenesis.
DISCUSSION
Apoptosis plays multiple beneficial roles in cancer, acting as
both a potent tumor suppressor and therapeutic effector mech-
anism. Conversely, various reports also suggest an oncogenic
function for apoptosis in some settings. For example, overex-
pression of anti-apoptotic BCL-2 proteins confers a favorable
prognosis in certain cancer types whereas genetic deletion of
the pro-apoptotic BH3-only proteins BID and PUMA inhibits
tumorigenesis in some settings (Berardo et al., 1998; Biswas
et al., 2013; Labi et al., 2010; Michalak et al., 2010; Reed,
1996). Moreover, caspase-dependent DNA damage has been
described following mitotic slippage and treatment with the
death-receptor ligand TRAIL (Lovric and Hawkins, 2010; Orth(B) U2OS cells transiently expressing CytoGFP and MitoCherry were treated wit
gH2A.X. Representative images are shown.
(C) Quantification of gH2A.X foci in cells displaying minority MOMP (ABT-737-trea
independent experiments.
(D) HeLa cells were treated as in (B) and subject to comet assay. Representative
(E) Quantification of comet tail moment following ABT-737 treatment. Data repre
(F–H) HeLa and HeLa overexpressing BCL-xL (F), wild-type MEF andMEF double
were treated as in (A) and western blotted for gH2A.X and actin.
(I) A549 cells expressing caspase-9 fused to a FKBP dimerization domain were tre
induce caspase-9 dimerization and activation. Cleavage of caspase-3 and gH2A
(J) Wild-type HeLa and U2OS cells and their Cad-deleted counterparts were trea
(K) Wild-type and Cad-deleted HeLa cells were treated as in (D) and used to perf
represent mean ± SEM of four independent experiments.
(L) Representative images of gH2A.X and TUNEL immunohistochemical staining
*p < 0.05, compared versus control. See also Figure S3.
Met al., 2012). Finally, following ethanol exposure, recovery from
apoptosis is associated with genomic instability and transforma-
tion, although it remains unclear whether apoptosis has a direct
causative role in this setting (Tang et al., 2012).
Our data demonstrate that by limited mitochondrial permeabi-
lization, the same core apoptotic machinery that protects from
cancer can now lead to caspase-dependent genomic instability
and promote transformation. We find that the ability of minority
MOMP to stimulate DNA damage requiresmitochondrial-depen-
dent caspase activation of the DNase CAD. Our finding that
repeated engagement ofminorityMOMP triggers genomic insta-
bility may be due to an excessive induction of DNA damage and/
or additionally a simultaneous inactivation of key DNA damage
response (DDR) pathways. Accordingly, we observe sub-lethal
caspase activation suffices to cleave PARP1, an important
player in the DDR, as well as ATM and KAP1 (data not shown)
both of have been shown or are predicted to be inactivated
following caspase-mediated cleavage (Smith et al., 1999; Van
Damme et al., 2005). Inactivation of ATM may also explain the
requirement for JNK in mediating gH2A.X phosphorylation fol-
lowing CAD activity. Potentially, inactivation of additional DDR
pathwaysmay exacerbate DNA-damage and genomic instability
initiated by minority MOMP.
MinorityMOMP-inducedDNAdamagemayplayvarious impor-
tant roles in cancer. For example, physiological triggers of mito-
chondrial apoptosis that fail to trigger cell death could promote
genomic instability and cancer. Further studies investigating the
impact of CAD deletion upon transformation and tumorigenesis
will help shed light on this. The ability of anti-cancer therapies to
triggerminorityMOMP-inducedDNAdamagemay have negative
consequences. We find that the BH3 mimetic ABT-737 can
induce DNA damage and genomic instability at doses compara-
ble to those achieved during clinical application of BH3mimetics.
In combination with oncogenic stress or tumor suppressor loss,
ABT-737 treatment promoted transformation. In cancer therapy,
this raises a cautionary paradox, namely that treating tumor cells
with an apoptosis-inducing therapy (such as BH3-mimetics) may
in itself be oncogenic. Supporting this, etoposide-induced chro-
mosomal translocations driving therapy-associated leukemia
have previously been shown to require caspase andCADactivity;
this possibly requires minority MOMP to initiate caspase activa-
tion (Hars et al., 2006; Sim and Liu, 2001). Second, minority
MOMP-induced DNA damage that is engaged by pro-apoptotich ABT-737 (5 mM) for 3 hr or H2O2 (25 mM) for 10 min and immunostained for
ted cells), control, and H2O2-treated cells. Data represent mean ± SEM of three
images are shown.
sent mean ± SEM of three independent experiments.
knockout for Bax and Bak (G), or HeLa versus HeLa knockdown for APAF-1 (H)
ated with indicated sub-lethal concentrations of homodimerizer (DM) for 3 hr to
.X was assessed by western blot.
ted and immunoblotted as in (A).
orm comet assay. Graph represents quantification of comet tail moment. Data
in small intestine of mice treated with ABT-737 (75 mg/kg) for 1 day (n = 3).
olecular Cell 57, 860–872, March 5, 2015 ª2015 The Authors 867
A B C
D E
Ponceau
COX IV 
Cyt c
β-tubulin
DOX (ng/ml):  -  2.5  1  -                
DOX (μg/ml):  -    -   -   1                WCE
DOX:  -   2.5
 ng
1 n
g
0.5
 ng
0.1
 ng
QVD:  -    -    -    -   -    -   +   +   +   +     -    +
  -   2.
5 n
g
1 n
g
0.5
 ng
0.1
 ng
1 μ
g
1 μ
g
ɣH2A.X 
actin
PARP 
tBID (short exp)
tBID (long exp)
F
CytoGFP MitoCherry DAPI Merge
Ctrl
DOX 
1 μg
DOX 
2.5 ng
DOX 
1 ng
Ct
rl
DO
X 
2.5
 ng
 
DO
X 
1 n
g 
0
2
4
6
8
10
C
el
ls
w
ith
m
in
or
ity
M
O
M
P
(%
)
LZRS BCL-XL
*
*
γH2A.X
α-Tubulin
FAS (ng/ml):  -  10  25 50  -  10  25  50
QVD:  -    -    -    -   +   +   +   +     
G H I
Ct
rl
FA
S /
 C
HX CH
X
0
2
4
6
8
10
C
el
ls
w
ith
m
in
or
ity
M
O
M
P
(%
)
U2OS LZRS U2OS BCL-XL
* *
Ct
rl
MG
13
2 
2.5
 μM
0
5
10
C
el
ls
w
ith
m
in
or
ity
M
O
M
P
(%
)
PDAC LZRS PDAC BCL-XL
* *
DOX 1 
(μg/ml):   -    +       -    +  
Me
lJu
So
 tB
ID
 
tet
ON
Me
lJu
So
wt
actin
tBID
*
DOX (ng/ml):    -        0.1      0.5       1       2.5  1 μg/ml
0
10
20
30
An
ne
xi
n
V
po
si
tiv
e
ce
ll s
(%
)
Figure 4. Sub-Lethal BH3-Only Protein and Apoptotic Stress Induces Minority MOMP and DNA Damage
(A) MelJuSo tBID tetON or wild-type cells were treated for 12 hr with 1 mg/ml of doxycycline (DOX), and cell lysates were probed for tBID.
(B) MelJuSo tBID tetON cells were treated for 6 hr with DOX and cell viability was assessed by Annexin V-based flow cytometry. Data represent mean ± SEM of
three independent experiments. *p < 0.05, compared to control.
(C) Cytosolic fractions from MelJuSo tetON tBID cells treated as in (B) were probed for cytochrome c. To induce apoptosis, 1 mg/ml DOX was used as a positive
control. WCE, whole-cell extract.
(D) MelJuSo tBID tetON expressing CytoGFP/MitoCherry were treated with DOX as in (A) and imaged by confocal microscopy. Arrows denote mitochondria
undergoing permeabilization.
(E) Quantification of cells undergoing minority MOMP. Data represent mean ± SEM of three independent experiments.
(F) MelJuSo tBID tetON were treated with DOX as in (A) and cell lysates were probed by western blot for gH2A.X, PARP, and tBID.
(G) U2OS cells stably expressing empty vector or BCL-xL were treated for 3 hr with FAS ligand (10 ng/ml) and CHX (1 mg/ml) and scored for the presence of
minority MOMP. Data represent mean ± SEM of three independent experiments.
(H) U2OS cells were treated for 3 hr with the indicated concentrations of FAS ligand and CHX (1 mg/ml), and western blot was performed for gH2A.X.
(I) PDAC cells were treated with MG132 (2.5 mM) for 3 hr, and minority MOMP was quantified. Data represent mean ± SEM of three independent experiments.
*p < 0.05, compared versus control. See also Figure S4.anti-cancer therapies has the potential to be mutagenic. This
could contribute to increased aggressiveness of relapsing tumors
following treatment and to the acquisition of drug resistance.868 Molecular Cell 57, 860–872, March 5, 2015 ª2015 The AuthorsIndeed, acquired resistance to the BH3 mimetic ABT-199 was
recently shown to be due to ABT-199-induced missense muta-
tions in BCL-2 (Fresquet et al., 2014).
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Figure 5. JNK Regulates the DNA Damage Response
(A) U2OS cells were treated for 3 hr with 10 mMABT-737, and phospho JNK1/2, ATM, and ATR were assessed by western blot. Ionizing radiation (2 Gy) was used
as a positive control.
(B) U2OS were treated with ABT-737 as in (A) in the presence or absence of Q-VD-OPh (10 mM) and immunoblotted for P-JNK1/2 and gH2A.X.
(C) Representative images of P-JNK1/2 immunohistochemical staining in small intestine of mice treated with ABT-737 (75mg/kg) for 1 day (n = 3); untreated mice
(n = 3) were used as control.
(D) HeLa cells were transiently transfected with siRNA for JNK1/2 and treated as in (A). Cell lysates were probed for total JNK1/2 and gH2A.X.
(E) As in (D), except that siRNA oligos targeting JNK1, JNK2, or both JNK1 and JNK2 together were used.
(F) U2OS cells were transfected with siRNA targeting CAD and treated with ABT-737. Cell lysates were probed for gH2A.X and P-JNK1/2.
See also Figure S5.Cell survival following minority MOMP may be even more
important in post-mitotic, non-renewable cells such as neurons.
Recently, neurons have been found to rapidly degrade cyto-
chrome c following MOMP in a manner dependent on the E3
ubiquitin-ligase PARC (Gama et al., 2014). Beyond promoting
cell survival, degradation of cytochrome c also has the potential
to limit minority MOMP-dependent DNA damage. Additionally,
removal of individual, permeablized mitochondria, particularly
under stressful conditions, may also affect the DNA-damaging
effects of minority MOMP. Along these lines, different studies
have found mitochondria are degraded in an autophagy-depen-
dent manner following permeabilization (Colell et al., 2007; Xue
et al., 2001).
A variety of non-apoptotic roles for mitochondrial dependent
caspase activation have been described, particularly in neurons
(Hyman and Yuan, 2012). These include caspase-dependent
dendrite pruning and AMPA receptor internalization (Li et al.,
2010; Simon et al., 2012). Minority MOMP could be a potential
mechanism to establish sub-lethal caspase activity in such
processes.
Besides the detrimental, oncogenic effects of minority MOMP,
our findings also raise potentially important therapeutic possibil-
ities. For example, manipulating minority MOMP to convert it to
complete MOMP or enhancing downstream caspase activity
may improve the cytotoxic effects of anti-cancer regimens.
Conversely, inhibition of caspase activity downstream of minor-
ity MOMP could mitigate undesirable cytotoxicity and thereby
reduce the systemic effects of chemotherapy.MEXPERIMENTAL PROCEDURES
Plasmids
CytoGFP plasmid was cloned as follows: the cDNA encoding 1XFKBPwas ob-
tained by PCR and inserted into the pEGFP-C1 plasmid via EcoRI and BamHI
restriction sites. The MitoCherry plasmid was obtained by sub-cloning the N
terminus sequence of AIF (N-terminal 1–90 amino acids) into pcDNA3 via Hin-
dIII and KpnI restriction sites, followed bymCherry fused with a glycine linker in
between KpnI and NotI, the FRB domain was inserted via NotI/XhoI. Both
CytoGFP and MitoCherry were transiently expressed and all treatments and
confocal imaging were done 24 hr later. For generating Dox-inducible, stable
expression in MelJuSo cells, C-terminally HA-tagged tBID-C in pLVX-Tight-
Puro (Clontech) was used as previously described (Rooswinkel et al., 2014).
Microscopy
Both live-cell imaging and immunostaining analysis were carried out using a
Nikon A1R confocal microscope (Nikon Instruments) with laser wavelengths
of 405 nm, 488 nm, 561 nm, and 636 nm. Where live-cell imaging was carried
out, the temperaturewasmaintained at 37CandCO2 at 5% v/v in a humidified
atmosphere. Images were acquired with a 603 NA 1.4 objective.
Micronuclei Assay
Cellswereplated ontocoverslips and treated for 36hrwith cytochalasinB in the
culturemedia at a final concentration of 3mg/ml.When themajority of cellswere
bi-nucleated, they were fixed in paraformaldehyde 4% in PBS for 10 min at
room temperature, washed once in PBS, and mounted with DAPI-containing
Vectashield. A minimum of 200 bi-nucleated cells was counted per condition.
Statistical Analysis
For comparison of multiple groups, two-way ANOVAwas usedwhile Student’s
t test was applied when comparing two groups. Analyses were performed us-
ing Prism 5.0 software (GraphPad).olecular Cell 57, 860–872, March 5, 2015 ª2015 The Authors 869
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Figure 6. Minority MOMP Promotes Genomic Instability
(A) HeLa cells were treated daily with ABT-737 or enantiomer (10 mM,Ctrl) at the indicated concentrations for either 5 (P5) or 10 (P10) passages and then scored for
micronuclei. Data represent mean ± SEM of three independent experiments.
(B) U2OS cells stably expressing BCL-xL (U2OS BCL-xL) or empty vector (U2OS LZRS) were treated as in (A) and assessed for micronuclei. Data represent
mean ± SEM of three independent experiments.
(C) MelJuSo tetON or wild-type MelJuSo cells were treated daily for ten passages with the indicated concentration of doxycycline (DOX) in the absence or
presence of Q-VD-OPh, and micronuclei were scored. Data represent mean ± SEM of three independent experiments.
(D) PDAC and 3T3-SA cells were treated daily for five passages with ABT-737 at the indicated concentrations, and clonogenic survival assay was performed in
media containing PALA (100 mM). Data represent mean ± SEM of three independent experiments.
(E) Genomic DNA was extracted from PALA-resistant PDAC, 3T3-SA, and WEHI-S clones, and Cad gene levels were quantified by qPCR. Data represent the
mean ± SD from triplicate samples from a representative experiment carried out twice independently.
(F) Representative images of PALA-resistant colonies from PDAC cells stably expressing BCL-xL (PDAC BCL-xL) or empty vector (PDAC LZRS). Cells
were treated daily for five passages with ABT-737 at the indicated concentrations, and clonogenic survival assay was performed in media containing PALA
(100 mM).
(G) Quantification of PALA-resistance clonogenic survival in PDAC BCL-xL versus PDAC LZRS cells. Data represent mean ± SEM of three independent ex-
periments.
(H) Cad expression in PDAC BCL-xL and PDAC-LZRS PALA resistant colonies. Data represent the mean from a representative experiment carried out twice
independently.
Where stated, *p < 0.05, compared versus control. See also Figure S6.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two movies and can be found with this article online at
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Figure 7. Minority MOMP Promotes Transformation and Tumorigenesis
(A and B) Primary mouse embryonic fibroblasts (MEF) were treated daily for seven passages with the indicated concentrations of ABT-737 and transduced with
E1A- and KRAS-expressing retrovirus. Representative images are shown in (A), and quantitation of the number of transformed colonies is depicted in (B). Data
represent mean ± SEM of triplicate samples for a representative experiment (out of three independent experiments).
(C) Primary p19Arf null MEFs or p19Arf null MEFs transduced with empty vector or BCL-xL-expressing retrovirus were treated for ten passages with ABT-737
(10 mM) in the presence or absence of Q-VD-OPh (10 mM), enantiomer (10 mM), or DMSO (Ctrl), and their anchorage-independent growth was assessed by soft
agar assay. Representative images for each condition are shown.
(D) Quantification of triplicate samples (mean ± SEM) from one representative soft agar assay (out of three independent experiments).
(E) Primary p19Arf null MEF were treated with ABT-737 (10 mM) or enantiomer (ENA, 10 mM) for ten passages. CD1-Nude female mice were injected subcuta-
neously with treated MEF and tumor growth was measured over time. Data are plotted as mean with error bars representing 95%CI (n = 15 for both treatments).
Applying Welch’s t test to the area-under-the-curve data produces a p value of 3.48 3 107 for the tumor growth rates.
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advice/expertise for analyzing the DNA damage response. S.M.M., D.A., and
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